Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
May 9th, 2018
17.5K views
In view of the 3Rs principle, respiratory models as alternatives to animal studies are evolving. Especially for risk assessment of respiratory substances, there is a lack of appropriate assays. Here, we describe the use of human precision-cut lung slices for the assessment of airborne substances.
Overview
This study presents a three-dimensional model using human precision-cut lung slices (PCLS) to assess cytotoxicity and immunomodulatory effects in an ex vivo environment. The model aims to evaluate the safety of airborne substances while mimicking human respiratory diseases.
Key Study Components
Area of Science
- Pharmacology
- Toxicology
- Respiratory Biology
Background
- Current assays for assessing respiratory substances are limited.
- The 3Rs principle encourages alternatives to animal studies.
- Human PCLS can provide insights into human-specific responses.
- Challenges exist in the organization and execution of PCLS techniques.
Purpose of Study
- To develop a reliable method for assessing the effects of airborne substances.
- To mimic human respiratory diseases in a laboratory setting.
- To enhance understanding of human tissue responses to toxic agents.
Methods Used
- Cannulation of the trachea and filling with agarose.
- Preparation of precision-cut lung slices (PCLS) for assays.
- Assessment of cytotoxicity using WST-1 and LDH assays.
- Microscopic evaluation of PCLS viability and responsiveness.
Main Results
- PCLS effectively mimic human respiratory responses.
- Demonstrated cytotoxic effects of tested substances.
- Provided a platform for studying cell-cell interactions in lung tissue.
- Highlighted the importance of technical skill in PCLS preparation.
Conclusions
- Human PCLS are a valuable tool for respiratory research.
- This model can improve risk assessment of airborne substances.
- Further development of techniques is necessary for broader applications.
Frequently Asked Questions
What are precision-cut lung slices?
Precision-cut lung slices are thin sections of lung tissue used to study respiratory responses in a controlled laboratory setting.
How do PCLS contribute to toxicology?
PCLS allow researchers to assess the cytotoxic effects of airborne substances on human lung tissue, providing insights into safety and risk assessment.
What are the main challenges in using PCLS?
Challenges include the technical skill required for preparation, the need for reliable infrastructure, and the variability in lung tissue.
Can PCLS be used for other species?
Yes, while primarily focused on human tissue, PCLS techniques can be adapted for use with other species.
What assays are commonly used with PCLS?
Common assays include WST-1 for cytotoxicity and LDH assays to measure cell membrane integrity.
How are PCLS prepared for experiments?
PCLS are prepared by cannulating the trachea, filling the lungs with agarose, and slicing the tissue into thin sections for analysis.
Executive Industry Relevance
Human precision-cut lung slices (PCLS) provide an ex vivo model to assess cytotoxicity and immunomodulatory effects of airborne substances using viable human tissue, supporting 3Rs-aligned risk assessment in pharmaceutical and occupational safety testing. The model enables evaluation of pro-inflammatory cytokine release, such as TNF-α and IL-1α, offering mechanistic insight into respiratory tissue responses relevant to target validation and safety profiling. This approach bridges in vitro limitations and in vivo variability, enhancing predictive confidence in early discovery for inhaled therapeutics and toxicant screening.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of immunomodulatory pathways by measuring cytokine and chemokine secretion in human lung tissue.
- Operational Value: Supports functional target de-risking through ex vivo assessment of substance-induced inflammatory responses.
- Predictive Value: Provides human-relevant data to prioritize compounds based on immunomodulatory potential before in vivo studies.
Screening & Assay Development
- Scientific Value: Delivers quantitative, normalized readouts (e.g., cytokine levels per total protein) for standardized compound evaluation.
- Operational Value: Establishes reproducible viability and inflammation assays using WST-1 and ELISA in a multi-well format.
- Scalability Value: Facilitates medium-throughput screening of substances with defined toxic and immunomodulatory endpoints.
Translational & Preclinical Research
- Translational Value: Maintains human tissue relevance from discovery through preclinical assessment of respiratory responses.
- Mechanistic De-risking: Clarifies whether observed effects stem from direct cytotoxicity or specific immunomodulation.
- Continuity Value: Supports progression from acute exposure modeling to chronic or repeated-dose study designs.
Pipeline & Workflow Integration
PCLS function as a human tissue-based platform in early discovery for mechanism probing and safety screening, informing lead identification decisions before preclinical commitment.
- Discovery Biology: Enables hypothesis testing of substance-induced immunomodulation via measurable cytokine outputs in native human lung architecture.
- Screening: Delivers standardized, quantitative viability and inflammation data suitable for assay optimization and compound ranking.
- Analytics: Generates normalized biochemical readouts (e.g., ELISA-based cytokine levels) and viability metrics to compare treatment conditions.
- Translational Research: Offers continuity in assessing human-specific responses across discovery and preclinical stages when supported by follow-up functional assays.
- Enterprise Reuse: Represents a reusable human tissue platform adaptable to multiple substance classes and respiratory endpoints beyond cytotoxicity.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence through human-relevant immunomodulatory profiling.
- Operational Value: Promotes assay standardization and reproducibility across laboratories using defined slicing and culture protocols.
- Strategic Value: Improves go/no-go decisions by reducing reliance on animal models and increasing human data early in development.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on human lung tissue responses.
Implementation Considerations
- Requires expertise in human tissue handling, agarose perfusion, and precision slicing to ensure slice viability and consistency.
- Dependent on access to fresh human lung tissue and validated infrastructure for tissue preparation and sterile culture.
- Necessitates standardization of slicing thickness, incubation times, and assay normalization (e.g., to total protein) for cross-experiment comparability.
- Involves adaptation considerations when applying the model to different species or disease-state tissues.
- Limited by donor variability and tissue viability thresholds, requiring QC metrics (e.g., <15% dead nuclei) to ensure data reliability.
Biopharma FAQs
Why measure cytokine secretion in PCLS for target validation?
Measuring pro-inflammatory cytokines like TNF-α and IL-1α in PCLS after substance exposure helps determine whether observed effects are due to specific immunomodulation rather than general cytotoxicity, supporting mechanistic de-risking in target validation.
How does isolating the test substance as an independent variable improve discovery pipeline decisions?
By exposing PCLS to defined concentrations of a substance (e.g., ammonium hexachloroplatinate) while controlling for viability, researchers can isolate its immunomodulatory effect, enabling clear structure-activity relationships and safer compound progression.
What do quantitative cytokine measurements in PCLS enable for safety assessment?
Normalized cytokine levels (e.g., per total protein) provide quantitative, comparable data across treatments and donors, allowing teams to set thresholds for pro-inflammatory risk and prioritize compounds with lower immunomodulatory potential.
Why are replication requirements important for PCLS data in cross-functional collaboration?
Running duplicate wells and repeated experiments accounts for donor variability and technical variance, ensuring that observed cytokine increases (e.g., TNF-α, IL-1α) are reproducible and suitable for shared interpretation across toxicology, pharmacology, and project teams.
What statistical analysis is needed before implementing PCLS data in go/no-go decisions?
Appropriate statistical tests (e.g., comparing treated vs. control cytokine levels) are required to determine significant immunomodulatory effects, ensuring that decisions are based on reliable, non-random observations from the assay.
Chapters in this video
0:05
Title
1:26
General Preparation of Human PCLS and Subsequent Exposure to Chemicals
4:28
Measurement of Chemically-induced Cytotoxicity in Human PCLS by WST-1 Assay
6:01
LDH Assay
7:29
Microscopic Viability Assay with Confocal Laser Scanning Microscope (cLSM)
9:49
Results: Representative Images of the Three-dimensional Microscopic Staining and Image Rendering of Human PCLS
10:59
Conclusion
